SAB-176の新興薬剤に関する洞察と市場予測：2032年

SAB-176は、SAb Biotherapeuticsが開発した4価の広域中和完全ヒトポリクローナル抗体治療薬候補であり、重症季節性インフルエンザ入院患者の治療開発においてヒトの生物学的免疫反応を活用します。同社独自の技術であるDiversitAbプラットフォームから生み出された新規の特異的標的治療薬は、A型およびB型インフルエンザウイルスに結合するように設計されています。また、必要に応じて毎年の菌株の変化に対応するように変更することもできます。

前臨床データから、SAB-176は多様なインフルエンザ株に対して広範な予防効果を示す可能性があることが示唆されています。重症の季節性インフルエンザに対する高活性のポリクローナル抗体療法は、重症患者を治療し、高齢者や免疫不全者などのハイリスク集団に防御抗体を提供できる可能性があります。また、ワクチンと同様に、必要に応じて毎年の株変動に対応するように変更することも可能です。

最近、同社はSAB-176の開発計画を発表しました。同社は2023年後半までに第IIb相試験を開始する予定です。さらに、同社は2025年までに第III相試験を開始する可能性があり、2024年までに進行中の第IIb相試験のトップライン結果を期待しています。

当レポートでは、主要7ヶ国におけるSAB-176市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 季節性インフルエンザに対するSAB-176の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 SAB-176市場評価

• 季節性インフルエンザに対するSAB-176の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における季節性インフルエンザに対するSAB-176の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: SAB-176, Clinical Trial Description, 2023
• Table 2: SAB-176, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: SAB-176 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: SAB-176 Market Size in the US, in USD million (2019-2032)
• Table 7: SAB-176 Market Size in Germany, in USD million (2019-2032)
• Table 8: SAB-176 Market Size in France, in USD million (2019-2032)
• Table 9: SAB-176 Market Size in Italy, in USD million (2019-2032)
• Table 10: SAB-176 Market Size in Spain, in USD million (2019-2032)
• Table 11: SAB-176 Market Size in the UK, in USD million (2019-2032)
• Table 12: SAB-176 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: SAB-176 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: SAB-176 Market Size in the United States, USD million (2019-2032)
• Figure 3: SAB-176 Market Size in Germany, USD million (2019-2032)
• Figure 4: SAB-176 Market Size in France, USD million (2019-2032)
• Figure 5: SAB-176 Market Size in Italy, USD million (2019-2032)
• Figure 6: SAB-176 Market Size in Spain, USD million (2019-2032)
• Figure 7: SAB-176 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: SAB-176 Market Size in Japan, USD million (2019-2032)

“"SAB-176 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SAB-176 for seasonal influenza in the seven major markets. A detailed picture of the SAB-176 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SAB-176 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAB-176 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

SAB-176 is a quadrivalent broadly neutralizing fully human polyclonal antibody therapeutic candidate developed by SAb Biotherapeutics that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company's proprietary technology, the DiversitAb platform, is designed to bind to Type A and B influenza viruses. It may also be modified to address annual strain changes when needed.

Preclinical data suggest that SAB-176 offers potentially broad protection against diverse influenza strains. A highly potent, polyclonal antibody therapy for severe seasonal influenza could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune-compromised. Like vaccines, it can also be modified to address annual strain changes when needed.

Recently the company announced the developmental plan for SAB-176. The company plans to begin a Phase IIb study by the second half of 2023. Moreover, the company anticipates that it might start the Phase III trial by 2025 and expects Phase IIb topline results of the ongoing trial by 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SAB-176 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on SAB-176 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAB-176 research and development activities in seasonal influenza across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SAB-176.
• The report contains forecasted sales of SAB-176 for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for SAB-176 in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAB-176 Analytical Perspective by DelveInsight

• In-depth SAB-176 Market Assessment

This report provides a detailed market assessment of SAB-176 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• SAB-176 Clinical Assessment

The report provides the clinical trials information of SAB-176 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAB-176 dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to SAB-176 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAB-176 in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of SAB-176 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAB-176 in seasonal influenza.

Key Questions

• What is the product type, route of administration and mechanism of action of SAB-176?
• What is the clinical trial status of the study related to SAB-176 in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAB-176 development?
• What are the key designations that have been granted to SAB-176 for seasonal influenza?
• What is the forecasted market scenario of SAB-176 for seasonal influenza?
• What are the forecasted sales of SAB-176 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to SAB-176 for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. SAB-176 Overview in seasonal influenza

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SAB-176 Market Assessment

• 5.1. Market Outlook of SAB-176 in seasonal influenza
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of SAB-176 in the 7MM for seasonal influenza
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SAB-176 in the United States for seasonal influenza
  • 5.3.2. Market Size of SAB-176 in Germany for seasonal influenza
  • 5.3.3. Market Size of SAB-176 in France for seasonal influenza
  • 5.3.4. Market Size of SAB-176 in Italy for seasonal influenza
  • 5.3.5. Market Size of SAB-176 in Spain for seasonal influenza
  • 5.3.6. Market Size of SAB-176 in the United Kingdom for seasonal influenza
  • 5.3.7. Market Size of SAB-176 in Japan for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options